Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 10 of 80« First...89101112...203040...Last »

AstraZeneca Quietly Kills Some Programs

AstraZeneca canceled its combination of PD-L1 durvalumab and CTLA-4 medication tremelimumab in pancreatic ductal carcinoma.

Read More »

Repatha successful in heart problems study

Amgen Inc. said its potent cholesterol fighter Repatha significantly reduced the risk of heart attacks, strokes and death in patients with heart disease.

Read More »

Eli Lilly Ends Another Solanezumab Phase 3 Study

Lilly has closed off another avenue for solanezumab, its once-promising experimental therapy for Alzheimer’s disease, after scrapping another Phase III study.

Read More »

Lundbeck bets on shark antibodies for new brain drugs

Danish drugmaker Lundbeck is betting that shark antibodies may offer a new way of getting drugs into the brain to fight Alzheimer’s and other diseases, after successful early research with privately owned U.S. biotech firm Ossianix.

Read More »

Possible liver injury added to Biogen MS drug label

The prescribing label for Biogen’s big-selling oral multiple sclerosis drug Tecfidera has been updated to include a warning of potential liver injury.

Read More »

Greenphire, Exostar Announce Partnership

Greenphire and Exostar announced a partnership that facilitates the adoption, accessibility and use of clinical research site payment solutions.

Read More »

Natural Compound Found in Herbs, Vegetables Could Improve Treatment of Triple-Negative Breast Cancer in Women

University of Missouri researchers have found that luteolin, a natural compound found in herbs such as thyme and parsley, and vegetables such as celery and broccoli, could reduce the risk of developing metastasis originating from triple-negative breast cancer in women.

Read More »

Bristol will not seek faster lung cancer approval

Bristol-Myers Squibb will not to seek accelerated U.S. approval for a combination of its two immunotherapy drugs as an initial treatment for lung cancer.

Read More »

Alcobra to stop testing sole drug for ADHD

Alcobra Ltd. said it would abandon evaluating its only experimental drug to treat attention deficit hyperactivity disorder (ADHD) after a failed late-stage study.

Read More »

Stimulant boosts function in patients recovering from depression

People recovering from depression but struggling with its effect on memory, concentration and cognitive function may benefit from the stimulant modafinil, according to results of a small study.

Read More »

Biogen: New Spinraza Data Worth Price Tag

Biogen’s staggering price tag for the spinal muscular atrophy drug Spinraza is likely to further ignite the controversies of drug pricing.

Read More »

Merck pulls ahead in lung cancer drug combo race

Merck & Co. has pulled ahead of rivals in the race to combine immunotherapy with other drugs as a treatment for lung cancer,.

Read More »

Robert Kennedy Jr. to head vaccine safety review

Vaccination skeptic Robert F. Kennedy Jr. said he would chair a presidential panel to review vaccine safety and science at U.S. President-elect Donald Trump’s request.

Read More »

Ear infection drug succeeds in late-stage trial

Drug developer Otonomy Inc. said its drug to treat acute otitis externa (AOE), an infection in the outer ear canal, met the main goal in a late-stage trial.

Read More »

Inotek’s glaucoma treatment fails late-stage study

Inotek Pharmaceuticals Corp. said its experimental glaucoma treatment failed a late-stage study, citing a stronger-than-expected placebo effect.

Read More »

New drug approvals fall to six-year low in 2016

2016 turned out to be a disappointing one for new drug approvals with the U.S. Food and Drug Administration clearing just 22 new medicines for sale, the lowest number since 2010 and sharply down on 2015’s tally of 45.

Read More »

Growth hormone deficiency drug fails study

OPKO Health Inc. said its experimental drug for GHD in adults failed to provide a statistically significant benefit over a placebo in a late-stage study.

Read More »

Top Harvard Scientist Retracts Diabetes Breakthrough Paper

A Harvard professor has retracted research that was once considered a breakthrough in diabetes research.

Read More »

Anthera’s cystic fibrosis drug fails late-stage study, shares tank

Anthera Pharmaceuticals Inc. said its drug to treat certain cystic fibrosis patients failed a late-stage study, sending the company’s shares tumbling nearly 70 percent in after-hours trading.

Read More »

Some Seattle Genetics drug trials placed on hold

Seattle Genetics said four people died in trials testing its experimental cancer drug, prompting the U.S. FDA to impose a clinical hold on several early-stage studies.

Read More »

Page 10 of 80« First...89101112...203040...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2017 Focus: Ad Agency Roundtable and more!


Ad Right Bottom

Main Navigation